A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing a common anti-diabetic medication. The treatment has already been tested on several patients and has been a huge success with clinical trials now being initiated around the world.
The biotech Bioxodes is using a molecule derived from tick saliva to stop blood clots. The Walloon company is focused on preventing thrombosis during procedures involving medical devices. The current gold-standard anticoagulant can cause unwanted bleeding and side effects; could a molecule derived from ticks really be safer?
Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christian Homsy, former Celyad CEO, will be presenting one of the keynote talks. In this BioVox interview, we asked him to share his thoughts on the challenges faced by a company that’s pushing boundaries in the oncology space.
Have you ever considered how scientists are able to count transparent cells in a see-through solution? Traditional methods involve dyes, microscopes, time and effort. Now there’s a new technology on the market: Ovizio Imaging Systems has developed a technical solution to this longstanding problem. Using an imaging technique called digital holographic microscopy, Ovizio’s devices perform cell counts by reconstructing 3D images using light. This new type of imaging provides quantitative information about cells, including their number, morphology and viability, all without a drop of dye!
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.
A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing a common anti-diabetic medication. The treatment has already been tested on several patients and has been a huge success with clinical trials now being initiated around the world.
The biotech Bioxodes is using a molecule derived from tick saliva to stop blood clots. The Walloon company is focused on preventing thrombosis during procedures involving medical devices. The current gold-standard anticoagulant can cause unwanted bleeding and side effects; could a molecule derived from ticks really be safer?
Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christian Homsy, former Celyad CEO, will be presenting one of the keynote talks. In this BioVox interview, we asked him to share his thoughts on the challenges faced by a company that’s pushing boundaries in the oncology space.
Have you ever considered how scientists are able to count transparent cells in a see-through solution? Traditional methods involve dyes, microscopes, time and effort. Now there’s a new technology on the market: Ovizio Imaging Systems has developed a technical solution to this longstanding problem. Using an imaging technique called digital holographic microscopy, Ovizio’s devices perform cell counts by reconstructing 3D images using light. This new type of imaging provides quantitative information about cells, including their number, morphology and viability, all without a drop of dye!
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.